| Identification | More | [Name]
Valganciclovir | [CAS]
175865-60-8 | [Synonyms]
5-amino-3-[1-(hydroxymethyl)-2-(l-valyloxy)ethoxymethyl]-6,7-dihydro-3h-imidazo[4,5-d]pyrimidin-7-one
valganciclovir
Valgancyclovir
5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one | [EINECS(EC#)]
1312995-182-4 | [Molecular Formula]
C14H22N6O5 | [MDL Number]
MFCD23701445 | [Molecular Weight]
354.362 | [MOL File]
175865-60-8.mol |
| Hazard Information | Back Directory | [Uses]
Antiviral. | [Definition]
ChEBI: The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine. | [Indications]
Valganciclovir (Valcyte) is
the L-valyl ester prodrug of ganciclovir. | [Brand name]
Valcyte (Roche). | [Clinical Use]
Oral valganciclovir is comparable to intravenous
ganciclovir for the treatment and suppression of CMV
retinitis in AIDS patients. | [Drug interactions]
Potentially hazardous interactions with other drugs
Antibacterials: increased risk of convulsions with
imipenem-cilastatin.
Antivirals: possibly increased didanosine
concentration; profound myelosuppression with
zidovudine - avoid if possible.
Mycophenolate: possibly increased concentrations of
both mycophenolic acid and ganciclovir.
Increased risk of myelosuppression with other
myelosuppressive drugs. | [Metabolism]
Valganciclovir is well absorbed from the gastrointestinal
tract and rapidly and extensively metabolised in the
intestinal wall and liver to ganciclovir. Valganciclovir is
eliminated in the urine as unchanged ganciclovir, mainly
by glomerular filtration and also active tubular secretion. | [storage]
Store at -20°C |
|
|